1. Home
  2. KSCP vs RNTX Comparison

KSCP vs RNTX Comparison

Compare KSCP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knightscope Inc.

KSCP

Knightscope Inc.

HOLD

Current Price

$3.44

Market Cap

58.1M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSCP
RNTX
Founded
2013
2001
Country
United States
United States
Employees
N/A
10
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
47.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
KSCP
RNTX
Price
$3.44
$1.78
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$17.00
$10.00
AVG Volume (30 Days)
867.9K
118.7K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.54
N/A
EPS
N/A
N/A
Revenue
$11,335,000.00
N/A
Revenue This Year
$218.66
N/A
Revenue Next Year
$54.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.91
N/A
52 Week Low
$2.92
$1.02
52 Week High
$10.13
$2.22

Technical Indicators

Market Signals
Indicator
KSCP
RNTX
Relative Strength Index (RSI) 43.12 68.65
Support Level $3.09 $1.08
Resistance Level $4.50 $2.18
Average True Range (ATR) 0.34 0.19
MACD -0.05 0.04
Stochastic Oscillator 17.24 81.65

Price Performance

Historical Comparison
KSCP
RNTX

About KSCP Knightscope Inc.

Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: